You are here: Industry Insights > Junshi Biosciences

News List

H1 of June: What’s been happening in pharma? Sarah Harding
June 15, 2020
The first half of June has seen some great news stories from the pharma industry. Still dominated by the COVID pandemic, and against a backdrop of strong innovation and collaboration, some of the top stories are summarized here.
Junshi and Eli Lilly have reached a USD 255 million COVID-19 Virus Antibody Authorization Deal CPhI.CN
May 06, 2020
On May 4, Junshi Biosciences and Eli Lilly Pharma announced that the two parties have reached an agreement to jointly develop and commercialize SARS-CoV-2 neutralizing antibodies against new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors prnasia
September 22, 2020
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administration (NMPA) of its next-generation fully human ...
Junshi Biosciences gets US FDA Breakthrough Therapy Designation for Toripalimab to treat nasopharyngeal carcinoma expresspharma
September 14, 2020
Chinese firm, Junshi Biosciences announced that the US Food and Drug Administration (FDA) has recently granted Breakthrough Therapy designation (BTD) to Toripalimab for the treatment of nasopharyngeal carcinoma.
Revitope And Junshi Biosciences Enter Into Research Collaboration And License Agreement To Explore Next Generation Immunotherapies With Precision-Targeted T-Cell Engaging Antibodies prnasia
July 14, 2020
Revitope will leverage its proprietary protein engineering platform together with Junshi's novel antibody components to develop first-in-class dual-antigen targeting cancer therapies.
Lilly Begins Study for Second Potential COVID-19 Antibody Treatment americanpharmaceuticalreview
June 17, 2020
Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
Junshi, Merck Collaborate on Head, Neck Cancer Treatment in China americanpharmaceuticalreview
June 11, 2020
Junshi Biosciences and Merck announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab (TUOYI®) in combination with Cetuximab (Erbitux®) ...
Lilly and Junshi Biosciences Initiate Phase I COVID-19 Trials contractpharma
June 10, 2020
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment prnewswire
June 09, 2020
Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
Junshi Biosciences, Merck Partner on SCCHN Combo Therapy contractpharma
June 02, 2020
To study anti-PD-1 mAb toripalimab (TUOYI) in combination with Cetuximab (Erbitux) in metastatic squamous cell carcinomas of the head and neck in China.

Previous page 1 2 Next page